childhood cases). NOTCH1 and CDKN2A/B were mutated/deleted in more than half of the cases, while an additional 37 genes were mutated/deleted in 4 to 20% of cases. We identified the IL7R-JAK pathway to be mutated in 27.7% of cases, with JAK3 mutations being the most frequent event in this group. Copy number variations were also detected, including deletions of CREBBP or CTCF and duplication of MYB. FLT3 mutations were rare, but a novel extracellular mutation in FLT3 was detected and confirmed to be transforming.
Furthermore, we identified complex patterns of pairwise associations, including a significant association between mutations in IL7R-JAK genes and epigenetic regulators (WT1, PRC2, PHF6). Our analyses showed that IL7R-JAK genetic lesions did not confer adverse prognosis in T-cell acute lymphoblastic leukemia cases enrolled in the UK ALL2003 trial.
Overall, these results identify interconnections between the T-cell acute lymphoblastic leukemia genome and disease biology, and suggest a potential clinical application for JAK inhibitors in a significant proportion of T-cell acute lymphoblastic leukemia patients. T-cell acute lymphoblastic leukemia (T-ALL) comprises a group of aggressive hematological tumors accounting for 10%-15% of pediatric and 25% of adult ALL cases, which are more frequent in males than females [1] [2] [3] . T-ALL development is a multi-step process in which different genetic lesions accumulate and alter the mechanisms controlling proliferation, survival, cell cycle and differentiation of T-cells. Loss of the CDKN2A (p16) locus and aberrant NOTCH1 signaling constitute the most predominant oncogenic lesions involved in the pathogenesis of T-ALL. Deletions of the CDKN2A locus in chromosome band 9p21 are present in up to 70% of T-ALL, 4 while up to 60% carry NOTCH1 activating mutations.
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NOTCH1 mutations lead to ligand independent cleavage and activation of the intracellular NOTCH1 part (ICN) and/or to stabilization of active protein. 2 NOTCH1 is an essential protein for T-cell development and aberrant activation of NOTCH1 in T-ALL affects many different pathways including the cell cycle, NFκB and PI3K/AKT pathways. In addition, T-ALL cases harbor chromosomal rearrangements that result in aberrant expression of transcription factor genes, such as TLX1, TLX3, TAL1, LMO2, and HOXA. [5] [6] [7] [8] [9] [10] These chromosomal aberrations are often used to classify T-ALL into subclasses associated with expression of one of these transcription factors, which in many cases also resembles a specific block in differentiation. 11 The mutational landscape of T-ALL also includes somatic mutations of IL7R, JAK3, JAK1, PTEN, and NRAS signaling proteins. [12] [13] [14] [15] Activating mutations in JAK1, JAK3 or IL7R lead to activation of the JAK/STAT pathway, resulting in stimulation of the proliferation and survival pathways in the leukemia cells. Recent next generation sequencing studies identified further recurrent mutations in proteins involved in mRNA degradation and translation (CNOT3 and RPL10) and in proteins implicated in the regulation of chromatin structure, including histone demethylases (KDM6A/UTX), and members of the polycomb repressive complex 2 (PRC2:
genes EZH2, SUZ12 and EED). [16] [17] [18] [19] Sequencing studies have suggested that on average 10 to 20 protein altering mutations can be detected in T-ALL cells, 18-20 but their exact frequency and patterns of co-occurrence have not been investigated in detail in large T-ALL cohorts.
Here, we used Haloplex targeted DNA capture followed by Next-generation sequencing studies have contributed significantly to our understanding of the genomic landscape of T-ALL. We recently profiled two cohorts of T-ALL using exome sequencing (67 cases) 18 and RNA-sequencing (31 cases), 24 while Zhang and colleagues profiled immature T-ALL cases (also known as early thymic or T-cell precursor T-ALL, ETP-ALL) ETP-ALL using whole genome sequencing (12 cases) 19 and targeted re-sequencing in 94 childhood T-ALL cases. To determine the spectrum of mutations present in both adult and childhood T-ALL, we selected 155 T-ALL cases (44 adult/111 childhood) to be analyzed by targeted re-sequencing. These cases were derived from two different cohorts from France (n= 80) and UK (n= 75). Based on all available sequence data, we selected 115 genes that were recurrently mutated in ALL or other hematological malignancies.
We used Haloplex enrichment to capture all exons of the selected genes, followed by Illumina sequencing. Two slightly different designs were used to profile the two T-ALL cohorts, which yielded a total of 12.9 Gb of sequence, with capture efficiencies of 45 to 60%.
The average coverage per sample was 209X. All genes were covered at >20X for at least 95% of their coding regions ( were identified in 103 genes as high-probability changes.
In order to validate the accuracy of our Haloplex assay and bioinformatics analyses (to which we will refer as Haloplex analyses), we sequenced 158 variants across 33 genes using Sanger sequencing (Supplementary Table 3 ).
Data from Haloplex target enrichment can be also used to identify copy number variations (CNVs) at the captured loci. 27 To this end, we normalized the coverage of all genes against the on-target mapped nucleotides across samples. Table 3) .
To determine the accuracy of Haloplex data for the detection of CNVs, we examined CNVs at the MYB (n= 155), CDKN2A (n= 95) and PTPN2 (n= 80) loci for which FISH, MLPA or arrayCGH data were available. Overall, 64% (9/14) of cases with MYB duplication, 93%
(69/74) of cases with CDKN2A deletion and 100% (6/6) of cases with PTPN2 deletion were identified by our Haloplex copy number analysis ( Figure 1B , Supplementary Table 4) .
Haloplex data predicted four additional cases with MYB duplication that have a lower normalized coverage when compared with those samples with true MYB duplications.
However, as they were not confirmed by any other method, we concluded that these were false positive results. Together, our data indicated that Haloplex re-sequencing data can be used for the identification of SNVs and CNVs with high confidence, with deletions being easier to detect than duplications. The detection of larger indels is difficult, especially for longer insertions. PTEN (12.3%), BCL11B (12.3%) and PTPN2 (7.7%) were in the range of previously reported frequencies. 2 Our data confirmed that JAK3 was frequently mutated in T-ALL (16.1%).
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Other recently identified mutations were also found including CREBBP (7.7%), 28 CNOT3
(5.2%) 18 and RPL10 (5.2%). 18 In contrast to AML, FLT3 mutations were rare among the T-ALL cases, although we identified one new mutation in the extracellular domain of FLT3 (S471C), which was confirmed to be a transforming mutation (Supplementary Figure 1) . Table 2 ). The most frequently affected pathway was transcriptional regulation, with mutations observed in as many as 81.9% of cases, followed
Genes with identified genomic lesions were grouped into functional pathways linked to T-ALL pathogenesis (Supplementary
by genes associated with cell cycle regulation (74.2%), chromatin modification (38.1%), genes encoding kinases (29.7%), phosphatases (26.5%) and DNA repair pathways (18.7%).
The mean number and spectrum of some of the identified genetic lesions closely correlated with patient age and T-ALL subtype. Alterations in PTPN2 (p=0.005; 18.2% vs. 3.6%), MYB (p=0.008; 22.7% vs. 6.3%) and CREBBP (p=0.039; 15.9% vs. 4.5%) were more prevalent among adult cases. In contrast, EZH2 (p=0.006, 13.5%) and RPL10 (p=0.106, 7.2%) aberrations were exclusively found in children, although the trend did not reach significance for RPL10.
We also found new and previously reported correlations between genetic lesions and T-ALL subgroups. Immature T-ALL cases had a lower incidence of CDKN2A (p<0.001, 13.3% vs. (Figure 3) .
The IL7R-JAK signaling cascade is an essential signaling pathway in hematopoiesis, and somatic mutations in IL7R, JAK1, JAK3 and STAT5 have been reported previously in T-ALL. 12, 15, 18, 31 However, the exact frequency of mutations for all members of the signaling pathway is unclear. In our series, sequence mutations/copy number variations of the IL7R, JAK1, JAK3 and STAT5 genes were found in 27.7% of cases, confirming that this signaling pathway is an important oncogenic axis in T-ALL ( Figure 4A) . Incidences of cases with genetic lesions of IL7R, JAK1, JAK3 and STAT5 genes were 9.7%, 4.5%, 16.1% and 4.5%, respectively. We found that 5.8% of cases carried combinations of these mutations (Supplementary table 2) .
We identified JAK3 as the most common targeted member of the pathway (16.1% of T-ALL cases). Most mutations were located within the pseudokinase domain, which has a regulatory function on kinase activity ( Figure 4A ). The M511I mutation was the most frequent. In 34.7% of JAK3 mutant cases the M511I mutation was detected together with a second mutation of JAK3 ( Figure 4B ). Seven patients had mutations/duplications of IL7R
The majority of JAK3 mutations identified in T-ALL have been confirmed as activating mutations, 15 but the transforming capacity of four JAK3 mutations identified in this study (Q283H, V678L, Q865E and E958K) was not studied previously. We expressed these mutants in Ba/F3 cells and confirmed that JAK3 V678L and Q865E were capable of transforming the cells to IL3 independent growth ( Figure 4C ). The JAK3 Q283H and Q865E mutants were not transforming ( Figure 4C ), suggesting that these may be passenger mutations. In summary, our results show that the IL7R-JAK signaling pathway is frequently mutated in T-ALL, with JAK3 being the most frequently altered gene (14.9% of T-ALL cases harbor transforming JAK3 mutations).
Having observed that the components of the IL7R-JAK axis were frequently mutated in T-ALL, we analyzed the possible associations between these mutations and the different T-ALL subgroups ( 
Clonal evolution has been documented in a range of hematological malignancies. 32 The proportion of sequencing reads reporting a given mutation can be used to identify whether mutations are present in the major clone or a subclone at the time of diagnosis.
Overall, we did not observe any specific genes that were more frequently mutated in subclones. As we had detected a high frequency of JAK3 mutations, we analyzed the 23 cases with JAK3 mutations in more detail ( Figure 5 ). Of these cases, 82.6% showed the presence of the JAK3 mutation in more than 35% of the cells, indicating that JAK3 mutations occur predominantly in the major clone at diagnosis. One of these cases carried a JAK3 M511I mutation at an allele frequency of 96.4%. As there were no copy number variations and the allele frequency for the SNPs present in that genomic region was around 100%, we conclude that copy number neutral loss of heterozygosity was responsible for this homozygous JAK3 mutation. In cases with two JAK3 mutations or with JAK3 and JAK1 mutations together, one JAK3 mutation was typically present in the major clone (>40% VAF in 9 out of 12 cases), with a minor clone having the second mutation (or both mutations).
These data confirm that a single JAK3 mutation can contribute to leukemia development, while the acquisition of an additional JAK3 or JAK1 mutation is likely to be of benefit for driving the growth of subclones during disease progression. We have performed targeted sequencing of a large cohort of T-ALL cases, coupled with a comprehensive study of their genetic background, in order to elucidate molecular lesions and their co-occurrence in patient samples. We used Haloplex enrichment to sequence the entire coding regions of 115 genes (known T-ALL driver genes or candidate driver genes). We showed that Haloplex sequencing for the detection of SNVs is highly specific and sensitive.
Deletions of entire genes were also detected with a high degree of accuracy. In contrast, the detection of gene duplications and indels, such as MYB duplications and insertions into the IL7R and FLT3 genes was less reliable, leading to false positive detection of duplications and false negative detection of indels. Similar findings were recently shown for targeted resequencing in acute myeloid leukemia, and it was shown that increased coverage could improve the identification of copy number alterations in Haloplex assays. 27 Haloplex analyses should not be preferred over aCGH or MLPA techniques for detection of copy number variations, especially for the detection of duplications.
Visual inspection of the reads for IL7R and FLT3 identified mutant alleles with indels, which had been missed by the analysis software. However, in most cases the mutant reads were missing, suggesting that the mutant exons had not been adequately captured during the target enrichment step. These observations highlight the need for further refinements to the alignment algorithms and the capture design for cancer samples, which will greatly increase the ability to detect large indels such as those present in IL7R and FLT3.
Once the Haloplex method was successfully validated, we used this approach to characterize the mutational profile of a cohort of 155 T-ALL cases. Targeted re-sequencing was performed in absence of germline/remission matched DNA and this should be considered. However, the fact that we identified known gene mutations/copy number variations at the same frequencies in our T-ALL cohort as reported in the literature, confirms both the validity of our approach and our cohort. Similar to observations in other tumors, only a few genes (NOTCH1, CDKN2A/B) were mutated or deleted in >50% of the T-ALL cases, while a large number were mutated in <20% of the cases. These observations corroborate the complexity and variation of events underlying T-ALL malignant transformation.
We observed that the IL7R-JAK signaling pathway was targeted in 27.7% of T-ALL. These findings have potential therapeutic implications, as JAK kinase inhibitors are known to target these alterations. 15 ,33-38 JAK3 is the most frequently mutated gene (16.1% of T-ALL cases)
within the IL7R-JAK signaling pathway. Based on the results described in this manuscript and our previously published work, 15 the transforming capacities of a total of 16 JAK3 mutants have been tested using the Ba/F3 in vitro cell system. Six of these 16 JAK3 mutants (R272H, Q283H, R403H, Q865E, R925S and E1106G) lacked transforming potential, illustrating that results from sequencing need to be confirmed by functional assays to distinguish driver mutations from passenger mutations. If we exclude the JAK3 mutations that lack transforming potential, then the frequency of cases with JAK3 mutations in our series is 14.9% (instead 16.1%).
Some T-ALL cases harbored two transforming JAK3 mutations, which suggests that those T-ALL cells that are dependent on a JAK3 mutation may gain proliferative advantage by mutating the second JAK3 allele. In line with this hypothesis, our clonality analysis of JAK3 mutated cases showed that in those with two JAK3 mutations or a JAK3 and JAK1 mutation together, one JAK3 mutation was typically present in the major clone, with the second mutation found in a lower percentage of the cells, most likely representing a minor clone.
We also investigated the prognostic impact of mutations of IL7R, JAK1 and JAK3, using data from the UKALL2003 trial, in particular because these mutations occur more frequently in immature T-ALL, a subgroup of T-ALL initially associated with a poor outcome in some studies.
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Despite the small subset of IL7R, JAK1 or JAK3 mutant T-ALL patients (n=10) in this cohort, it appeared that in general these patients fared well. It should be noted that the outcome of immature T-ALL patients has improved since initial reports of this subtype, and that more recent data from UKALL2003 and COG AALL0434 suggest immature T-ALL patients may not have worse outcome with intensified therapy. 23, 40 In fact, seven of the 10 patients with mutations within the IL7R-JAK pathway received very intensive chemotherapy based on risk stratification. Our data provide no evidence that IL7R, JAK1 and JAK3 mutations are a consistent marker of poor prognosis. Nevertheless, it might be that immature T-ALL cases harboring IL7R-JAK mutations would benefit from the use of JAK inhibitors in T-ALL trials, since it might reduce the toxic side effects from high-dose chemotherapy treatments. The efficacy of ruxolitinib (JAK1/2 inhibitor) was recently demonstrated in murine xenograft models of immature T-ALL. 41 Of interest, both JAK/STAT pathway activation and ruxolitinib efficacy were independent of the presence of JAK/STAT pathway mutations, raising the possibility that the therapeutic potential of ruxolitinib in T-ALL extends beyond those cases with JAK mutations. 41 Further studies are warranted to clarify this issue.
Importantly, we have found statistically significant associations between gene mutations and signaling pathway-groups or T-ALL patient characteristics. These include previously CJH, EC, CV, JC wrote the manuscript; CJH, EC and JC supervised the study.
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Sequence information
Reads passing filtration (Gb and JAK1 mutations occur together, while a minor clone has the second mutation. 
Supplementary Methods

DNA samples
Validation of identified genomic lesions
We sequenced 158 selected variants (Supplementary Table 3 ) using Sanger sequencing. Analysis of the chromatograms from Sanger sequencing was performed using CLC Main Workbench 6 (CLC Bio).
Western blot analyses
Cells were lysed in cold lysis buffer containing 5 mM Na 3 VO 4 and protease inhibitors (Complete tablets, Roche). The proteins were separated on NuPAGE NOVEX BisTris 4%-12% gels (Invitrogen) and transferred to PVDF membranes. Subsequent
Western blot analysis was performed using primary antibodies directed against JAK1
(Millipore), JAK3, phospho-STAT5, (Cell Signaling), phospho-JAK1, STAT5 (Santa Cruz Biotech.) and β-actin (Sigma). Anti-phospho-JAK1 antibody was used to detect both phosphorylated JAK1 and JAK3. Western blot detection was performed using secondary antibodies conjugated with horseradish peroxidase (GE Healthcare) and western blot lightning plus-ECL (PerkinElmer).
Statistical analyses
Statistical analyses were carried out using SPSSstatistics v21. Pearson's X 2 Fisher's exact tests were performed to test significance levels for nominal data distributions, whereas the Mann-Whitney U test was used for continuous data.
Validation of the newly identified FLT3 S471C mutation
The FLT3-S471C variant was generated by GenScript, and was cloned into the MSCV-GFP vector. Viral vector production, retroviral transduction and culture of Ba/F3 cells were performed as previously described. 1 Ba/F3 cells expressing the FLT3-ITD (W51 mutation, Kelly et al. 2 ) and FLT3-D835Y were previously described. 3 Western blot analyses were performed as indicated above using antibodies directed against FLT3, STAT5 (Santa Cruz Biotech.), anti-phosphoFLT3 (Tyr591), phospho-STAT5 (Cell Signaling) and β-actin (Sigma). Immunoprecipitations was not
Supplementary Results
In our association analyses, the putative JAK3 passenger mutants (JAK3 Q283H and Q865E mutants that were unable to transform Ba/F3 cells) were initially considered as mutants. We performed the same association analyses excluding those JAK3 passenger mutant cases (scored now as wild type).
Then, the frequency of cases with IL7R-JAK mutations in our series is 26.5% (instead 27.7%). All the associations we found with the IL7R-JAK positive cases remained significant as shown in the table below.
IL7R-JAK signaling pathway
Wt (n=114) Mut (n=41) P 
Type of Association Clinical
